Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GI198745 Clear all

Conditions: Prostatic Hyperplasia
Interventions: FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypogonadism
Interventions: dutasteride, placebo; Drug
Lead sponsor: The Miriam Hospital; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Prostate Cancer
Interventions: Dutasteride, Placebo; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alcohol Related Disorders, Alcoholism, Alcohol Abuse
Interventions: Dutasteride; Drug
Lead sponsor: UConn Health; Other
Eligibility: 21 Years to 55 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Prostatic Hyperplasia
Interventions: GI198745; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Neoplasms, Prostate
Interventions: Dutasteride, Matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 58
States / cities: Little Rock, Arkansas • Beverly Hills, California • Laguna Hills, California + 54 more

Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions: dutasteride; Drug
Lead sponsor: Urology of Virginia; Other
Eligibility: 50 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Norfolk, Virginia • Virginia Beach, Virginia

Conditions: Prostate Cancer
Interventions: Bicalutamide, Dutasteride, Finasteride, Radiation; Drug · Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: dutasteride; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy
Interventions: Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Benign Prostatic Hyperplasia
Interventions: Tamsulosin; Drug
Lead sponsor: Siami, Paul F., M.D.; Other
Eligibility: 50 Years and older · Male only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Adenocarcinoma of the Prostate
Interventions: STA9090, STA9090 with Dutasteride; Drug
Lead sponsor: Toni Choueiri, MD; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer, Localized Prostate Cancer
Interventions: Enzalutamide, Abiraterone acetate, Prednisone, Dutasteride, Degarelix; Drug
Lead sponsor: Kenneth Pienta, MD; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Abiraterone acetate, Dutasteride, Prednisone; Drug
Lead sponsor: Mary-Ellen Taplin, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 4
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Alcohol Related Disorders, Alcoholism, Alcohol Abuse
Interventions: dutasteride + ethanol, placebo medication + ethanol, dutasteride + placebo alcohol, placebo medication + placebo alcohol; Drug
Lead sponsor: UConn Health; Other
Eligibility: 21 Years to 45 Years · Male only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Hypogonadism, Hypogonadism, Male
Interventions: Nanomilled testosterone, Nanomilled dutasteride, commercially available dutasteride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Torrance, California • Louisville, Kentucky • Baltimore, Maryland + 3 more

Conditions: Contraception, Hypogonadism
Interventions: Oral Testosterone, Leuprolide (Lupron), Dutasteride; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Benign Prostatic Hyperplasia
Interventions: Dutasteride; Drug
Lead sponsor: Urologic Consultants of Southeastern PA; Other
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Bala-Cynwyd, Pennsylvania

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: University Urological Associates Inc.; Other
Eligibility: 50 Years to 74 Years · Male only
Enrollment: 6,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Prostatic Hyperplasia
Interventions: Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Evansville, Indiana • Austin, Texas

Conditions: Neoplasms, Prostate
Interventions: Dutasteride, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 8,231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 297
States / cities: Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 236 more

Conditions: Prostate Cancer
Interventions: Enzalutamide, Leuprolide, Dutasteride; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Prostate Cancer
Interventions: avodart, Placebo; Drug
Lead sponsor: Bay State Clinical Trials, Inc.; Other
Eligibility: 35 Years to 90 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Hypogonadism, Hypogonadism, Male
Interventions: Nanomilled testosterone, commercially available dutasteride, Nanomilled dutasteride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Tacoma, Washington

Search by objective public record fields.

Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects

Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement

Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies

Pharmacokinetic Study of Single Dose Dutasteride in Healthy Subjects

A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.

Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men

Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy

PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue

Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Pharmacogenetics of Alcohol: Treatment Implications

28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men

Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone

A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart

The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage

A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation

Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride